Recent research and developmental strategy of anti-asthma drugs.

摘要: Extensive research over the past decade has provided information about pharmacotherapy of bronchial asthma (BA). Anti-asthma drugs are classified into two categories: relievers (for relief attack symptoms) and controllers prevention symptoms). This paper aims to review recent advancements anti-asthma that controller medicines. The mainly act on immune inflammatory responses in BA development. 1) Immunomodulators. Drugs response immunosuppressors immunomodulators, including immunopotentiators. immunomodulation Th1 Th2 imbalance is first strategy because allergic thought be caused by Th2-polarized immunity. Suplatast a novel immunomodulator can adjust Th1/Th2 shows clear clinical efficacy against BA. approach shifted from more theoretical conceptual model one supported evidence efficacy.2) Anti-inflammatory agents. Corticosteroids,mast cell stabilizers autacoid inhibitors anti-inflammatory agents for superiority combined therapy inhaled corticosteroids long-acting beta2 agonists evident. potent synergic effect compared alone. Currently, under development affecting lipid mediators. prostaglandin (PG) D2 antagonist, PGE2, EP3 agonist PGI2 being considered addition well-established leukotriene thromboxane A2 inhibitors. New strategies therapeutics described this review.